Comparison of In vivo toxicity and anti-glatiramer acetate IgG antibody titers in rats Treated with glatiramer acetate (Copaxone) and follow-on glatiramer acetate (FOGA) products

被引：0
|
作者：
Konya, A. [1 ]
Timan, B. [2 ]
Ashkenazi, N. [2 ]
Bursztyn, D. [2 ]
Gyure, L. [1 ]
Vardi, M. [2 ]
Alexander, J. [3 ]
Loupe, P. [4 ]
Nock, S. [5 ]
机构：
[1] Teva Pharmaceut Ind Ltd, Debrecen, Hungary
[2] Teva Pharmaceut Ind Ltd, Netanya, Israel
[3] Teva Pharmaceut Ind Ltd, Denver, CO USA
[4] Teva Pharmaceut Ind Ltd, Overland Pk, KS USA
[5] Teva Pharmaceut Ind Ltd, Redwood City, CA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P678
引用
收藏
页码：337 / 337
页数：1
相关论文
共 43 条
  • [21] Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate
    Healy, Brian C.
    Glanz, Bonnie I.
    Zurawski, Jonathan D.
    Mazzola, Maria
    Chitnis, Tanuja
    Weiner, Howard L.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 394 : 127 - 131
  • [22] Time Dependent Ex Vivo RNA Expression Analysis of Monocytes Derived from Glatiramer Acetate Treated Multiple Sclerosis Patients
    Goertsches, Robert H.
    Hecker, Michael
    Thamilarasan, Madhan
    Koczan, Dirk
    Thiesen, Hans-Juergen
    Zettl, Uwe K.
    NEUROLOGY, 2010, 74 (09) : A421 - A421
  • [23] Comparative Long-Term Preclinical Safety Evaluation of Two Glatiramoid Compounds (Glatiramer Acetate, Copaxone®, and TV-5010, Protiramer) in Rats and Monkeys
    Ramot, Yuval
    Rosenstock, Moti
    Klinger, Ety
    Bursztyn, Dizza
    Nyska, Abraham
    Shinar, Doron M.
    TOXICOLOGIC PATHOLOGY, 2012, 40 (01) : 40 - 54
  • [24] Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups
    Pavelek, Zbysek
    Novotny, Michal
    Soucek, Ondrej
    Krejsek, Jan
    Sobisek, Lukas
    Sejkorova, Ilona
    Masopust, Jiri
    Kuca, Kamil
    Valis, Martin
    Klimova, Blanka
    Stourac, Pavel
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 53
  • [25] Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures, induced by pentylenetetrazol via protection of myelin sheath
    You, Yu
    Zhao, Yaqun
    Bai, Hui
    Liu, Zhiliang
    Meng, Fanxin
    Zhang, Hua
    Xu, Ruxiang
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 49 (03) : 366 - 370
  • [26] CCL2 (MCP-1) and CCL5 (RANTES) levels in the peripheral blood of multiple sclerosis patients treated with glatiramer acetate (Copaxone)
    Losy, J
    Michalowska-Wender, G
    Kudrynska, A
    Wender, M
    FOLIA NEUROPATHOLOGICA, 2005, 43 (03) : 153 - 155
  • [27] The use of in vivo 1H-magnetic resonance spectroscopy for evaluating the efficacy of treatment of patients with relapsing-remitting multiple sclerosis with copaxone (glatiramer acetate)
    Rozhkova, Z.
    Kobys, T.
    Myalovitska, O.
    Lobanova, I.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 236 - 237
  • [28] A comparison of outcomes among multiple sclerosis patients treated with glatiramer acetate injection or high-dose interferon Beta-Ia
    Castelli-Haley, J.
    Lage, M. J.
    Oleen-Burkey, M.
    VALUE IN HEALTH, 2007, 10 (06) : A387 - A387
  • [29] Usage of anti-MOG B cell and T cell transgenic mice model to evaluate effects of immunomodulating therapies in EAE -: A pilot study with Copaxone® (glatiramer acetate)
    Ziemssen, T.
    Dartsch, S.
    Marggraf, M.
    Reichmann, H.
    Schneider, H.
    MULTIPLE SCLEROSIS, 2006, 12 : S55 - S55
  • [30] Long-term treatment with Glatiramer Acetate induces specific antibodies in treated MS patients; they start as IgG1 but are IgG4 in the long term
    Basile, E
    Gibbs, E
    Aziz, T
    Oger, J
    MULTIPLE SCLEROSIS, 2005, 11 : S162 - S163
12345